Cuprous Pharmaceuticals

Cuprous Pharmaceuticals is a Canadian biotechnology company specializing in the development of novel nanomedicines using its proprietary Metaplex platform. The Metaplex technology utilizes transition metal coordination chemistry (specifically copper complexation) to encapsulate and deliver poorly soluble or sparingly soluble small molecules inside lipid-based nanoparticles. This approach overcomes drug delivery and solubility barriers, reduces peak plasma concentration (Cmax)-related toxicities, and enhances therapeutic efficacy. The company's primary therapeutic focus is in oncology, immuno-oncology (inducing immunogenic cell death), and infectious diseases. Cuprous collaborates with academic institutions like the University of British Columbia and BC Cancer to advance its pipeline of metal-coordinated therapeutics toward clinical development.